Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Atopic Dermatitis and Psoriasis

NCT06982352 is registered in ClinicalTrials.gov with LAPIX Therapeutics Inc. as lead sponsor.

NCT NCT06982352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06982352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Atopic Dermatitis and Psoriasis
Lead sponsor
LAPIX Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 15, 2025
Completion date
April 15, 2026
Enrollment
48 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad), psoriasis (pso)